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Abstract
Purpose: Outpatient parenteral antimicrobial therapy (OPAT) is a therapeutic option meant to
conserve healthcare resources when treating infections requiring the administration of IV
antibiotics over a prolonged treatment course. In November 2016 at Franciscan Alliance
Indianapolis, a dedicated pharmacist was hired to build a formal OPAT program for all patients
discharged on IV antimicrobials under the care of the infectious disease physician group. The
number of “good catch” events observed since the program’s formal inception has encouraged
the creation of this study designed to examine the impact of this program on patient outcomes
and antimicrobial stewardship.
Methods: This was a retrospective chart review of adult patients with a discharge order for at
least one IV antibiotic from Franciscan Health Indianapolis from December 1st, 2016 to May
31st, 2017. Patients receiving OPAT consults during their index hospital stay were compared to
patients with similar infections who did not receive a consult. Patients residing in a nursing
home or long-term care facility prior to admission were excluded from the analysis. Comparisons
between patients with and without a readmission were also conducted in order to identify
commonalities and differences in risk factors between groups. Demographic information
collected included: the indication for parenteral antimicrobial therapy, sex, age, weight, and the
type of provider prescribing the antimicrobials. The primary objective was 30-day readmission
rate, with each instance being stratified based on the reason for readmission. Secondary
objectives included: type of infection, antibiotic type, disposition at discharge, and duration of
treatment. At least 122 patients were needed in each arm in order to detect a difference of 50
percent between treatment groups with a power of 80 percent for the primary objective.
Results: No statistically significant difference between the readmission rates of the consult
group and the non-consult group was observed (14.73% versus 31.82%, p>0.05). The usage of
antipseudomonal coverage (39.58% versus 86.36%, p<0.0001) and ceftriaxone (9.47% versus
45.45%, p<0.0001) was significantly lower in the consult group, demonstrating the potential
improvements in antimicrobial stewardship an OPAT program can provide. Use of agents
requiring therapeutic drug monitoring (TDM) was higher in the non-consult group, specifically
vancomycin (86.36% versus 41.05%, p<0.001) and gentamicin (6.32% versus 22.73%, p<0.05).
Furthermore, patients discharged to an extended care facility (ECF) or a short-term acute
rehabilitation center (SAR) after receiving a consult were less likely to be readmitted (16.23%
versus 54.55%, p<0.001). The difference in use of drugs requiring TDM for patients sent to a
SAR with a consult may also have contributed to this trend (50.46% versus 100%, p<0.0001).
Conclusion: The OPAT service did not show a statistically significantly reduction in the 30-day
readmission rate during the first 6 months of the program. However, the number of patients
without a consult meeting the inclusion criteria was markedly lower than anticipated, which led
to the study being underpowered. Additionally, use of the program was associated with improved
antimicrobial stewardship through reduced use of antipseudomonal coverage and ceftriaxone as
well as reduced readmissions in patients requiring SAR placement.

Background
Outpatient parenteral antimicrobial therapy (OPAT) is defined as the administration of
parenteral antimicrobials for at least 2 doses given on different days and without a hospitalization
between.1 Rather than requiring a patient to remain in a hospital solely to receive antimicrobial
therapy after being medically cleared to go home, he or she can be discharged for a portion of the
therapy. The ability to send a patient on intravenous antimicrobial therapy has been shown to
potentially reduce the high costs associated with chronic administration of antibiotics,2 increase
the patient’s quality of life by granting improved flexibility and convenience, and reduce the
likelihood that the patient will acquire a nosocomial infection. As a result, OPAT has grown at a
breakneck pace since its inception in the 1970s, and projections of its market share predict that it
will soon reach the multibillion-dollar-a-year threshold.1
Furthermore, input from pharmacists to assist in the appropriate selection of
antimicrobials and durations of therapies has the potential to attempt to stem the rising tide of
resistant microorganisms. The interventions related to spectrum and duration can lead to vastly
reduced rates of adverse effects due to unnecessary antimicrobial use and can also reduce the
likelihood that the patient may encounter an infection caused by a resistant organism later in
life.3 Additionally, it may reduce the rate of multidrug resistant organisms, which is especially
critical for patients who must be admitted but are also most at risk. Through appropriate
recommendations related to the spectrum and duration of therapy, selection of resistant
microorganisms can be minimized, which partially mitigates these risks.
In addition to pharmacist involvement, interprofessional collaboration and careful
selection of patients designated to receive OPAT are critical to ensuring successful therapy.
Beyond the clinical expertise offered by the ID physicians, coordination of social support and
third-party authorizations between case management and pharmacy contribute significantly to a
patient’s ability to receive appropriate therapy. Additionally, in patients for whom adequate
monitoring and follow up cannot be guaranteed, complications related to vascular access devices
and drug adverse reactions can lead to significant harm. 4 Therefore, both social and medical
evaluations should be integral steps in the process utilized to identify patients appropriate to
receive OPAT.
In November 2016 at a community hospital, a dedicated pharmacist was hired to continue
to build a formal OPAT program for all patients discharged on IV antimicrobials under the care
of the infectious disease physician group. Through a collaborative practice agreement, the
pharmacist’s responsibilities upon consultation were to evaluate and make recommendations
related to antimicrobial selection, therapy duration, and monitoring parameters, as well as the
provision of patient education and assistance to case managers involved with disposition
planning. Upon discharge from the hospital, the pharmacist continued weekly monitoring
throughout the duration of therapy of all patients that received such consultative services during
their inpatient stay. Due to the relatively new nature of this OPAT program and the number of
“good catch” events observed since its formal inception, this study sought to examine the impact
of an OPAT program for those patients receiving OPAT at hospital discharge.
Methods
This was a retrospective observational cohort study examining adult patients with an
order for an IV antibiotic following discharge from a community hospital within the time period
of December 1, 2016 to May 31, 2017. Patients who received OPAT consults during their index
hospital stay were compared to those patients who did not in the same time period. Patients

residing in a nursing home or long-term care facility prior to admission and those also receiving
oral antimicrobials were excluded from the analysis. The primary objective was thirty-day
readmission rate, which was stratified by the reason for readmission (ID process, drug adverse
event, or unrelated reason). Type of infection, antimicrobial selection (including agents with
antipseudomonal activity or requiring therapeutic drug monitoring), duration of treatment, and
disposition at hospital discharge were also collected from the electronic medical record.
Statistical Analysis
The Fisher’s Exact Test and Chi Square Analyses were utilized, as appropriate, for
nominal endpoints including: the 30-day readmission rate, use of each antimicrobial class, and
the use of agents with a high risk of a C. difficile infection, such as ceftriaxone, or requiring
therapeutic drug monitoring. The Wilcoxon Ranked Sum Test was utilized to determine the
significance of differences in length of stay and duration of therapy. Statistical Package for the
Social Sciences software available through Butler University was utilized for these analyses. All
other variables and baseline demographic information were described utilizing descriptive
statistics.
Results
No statistically significant differences between groups were seen in terms of
demographic information (Table 1).
Table 1: Demographics

Median Age
(IQR)
Sex (%)
M
F
Median
Weight
(IQR)
Median
Index LOS
(IQR)

OPAT
Consult
(N=95)
61 (21)

No OPAT
Consult
(N=22)
63 (26)

p Value

42 (44)
53 (56)

6 (27)
16 (73)

0.146

91 kg
(35 kg)

79 kg
(41 kg)

0.085

6 (5)

7 (8)

0.313

0.503

No statistically significant difference between the readmission rates of the OPAT consult
group and the non-consult group was observed (14.73% vs 31.82%, p=0.07). Additionally, the
proportion of patients requiring a change in disposition did not vary significantly between
groups, with 39 (41%) patients with a consult and 12 (55%) patients without a consult being
discharged to a short-term acute rehabilitation center (SAR) or extended care facility (ECF)
(P=0.252). Bacteremias with various sources of infection were the most common type of
infection requiring therapy in both groups, constituting 35% of patients in the OPAT consult
group and 59% of the patients without a consult. Differences in provider type and indication for

therapy between groups were statistically significant (p=<<0.0001; 3 x 10-12). The median total
days of therapy for patients with a consult was 24 days in comparison to 25 days in the nonconsult group (p=0.095).
The most significantly differing trends between groups were evident in prescribing
practices. The usage of antipseudomonal coverage was significantly lower in the OPAT consult
group (39.58% vs 86.36%, p=0.00006). Additionally, utilization of ceftriaxone, known for its
potential to predispose patients to C. difficile infections, was also significantly lower in the
OPAT consult group (9.47% vs 45.45%, p=0.00004). Differences in other key antibiotics that
serve as stewardship targets were also seen with piperacillin-tazobactam, cefepime, and
vancomycin (Table 2). Also of interest, patients without an OPAT consult discharged to a SAR
or ECF were significantly more likely to have been prescribed agents requiring therapeutic drug
monitoring (100% vs 59.56%, p=0.038) and to have later required readmission (54.55% vs
16.22%, p=0.001).
Table 2: All Patients

Disposition Change

OPAT Consult
(N=95)

No OPAT Consult
(N=22)

p Value

39 (41%)

12 (55%)

0.252
3 x 10-12

Indication for Therapy
Empyema
Osteomyelitis
Bacteremia
Intra-Abdominal
Skin and Soft Tissue (SSTI)
Other

7
11
33
10
25
9

2
2
13
3
0
2

Primary Provider Type
Pulmonary
Cardiology
Surgery
Internal Medicine
Oncology

5
10
25
52
3

7
1
4
8
2

24 (19)

25 (17)

Median Days of Therapy
(IQR)

0.000095

0.095

Table 3: Drug Choice
Drug Choice
Ampicillin
Ampicillin-Sulbactam
Piperacillin-Tazobactam
Cefazolin
Ceftazidime
Ceftriaxone
Cefuroxime
Cefepime
Meropenem
Ertapenem
Gentamicin
Tobramycin
Vancomycin
Linezolid
Daptomycin
Metronidazole
Clindamycin
Fluconazole
Antipseudomonal Agents

OPAT Consult
(N=95)
5
12
13
15
1
9
1
10
8
4
6
0
39
0
1
2
2
2
37

No OPAT Consult
(N=22)
2
2
11
3
0
10
1
7
5
1
5
4
19
2
0
5
2
2
19

P Value
0.495
0.645
0.0001
0.801
0.203
0.00004
0.255
0.011
0.054
0.944
0.017
0.0002
0.0001
0.023
0.213
0.0002
0.104
0.104
0.00006

Readmitted Subgroup
When examining readmitted patients as a subgroup, several differences between those
receiving a consult and those without were seen (Table 4). Significant differences in the
indications for therapy in this population were seen (p=0.009), with bacteremias and SSTIs as the
most common in the OPAT consult (71%) and non-consult (43%) groups, respectively.
Additionally, a trend was seen showing that patients in this subgroup without a consult were
more likely to have experienced a change in disposition (85.71% vs 42.86%, p=0.061).

Table 4: Readmitted Patients

Median Age (IQR)
Sex
Male
Female
Indication for Therapy
Osteomyelitis
Bacteremia
Intra-Abdominal
Skin and Soft Tissue
Other

OPAT
Consult
(N=14)

No
OPAT Consult
(N=7)

P Value

61 (16)

64 (26)

0.711

8
6

5
2

0.525
0.009

2
3
2
6
1

1
5
1
0
0

6 (2)

7 (3)

0.352

12 (14)

9 (6)

0.368

8
6

1
6

Disposition Change

6 (43%)

6 (86%)

0.061

Median Total Days of
Therapy (IQR)

28 (24)

28 (27)

0.190

2
3
9

3
1
3

Median Index Length
of Stay (IQR)
Median Days to
Readmission (IQR)
Disposition at
Discharge
Home
ECF or SAR

Reason for
Readmission
ID Process
Drug Adverse Event
Unrelated Process

0.061

0.216

Discussion
No statistical significance in terms of the primary objective, thirty-day readmission rates,
was seen in the study. However, the more than two-fold difference in readmission rate can
certainly be seen as clinically significant. The readmission rate of 14.74% was also similar to the
21.5% readmission rate reported by another study, which somewhat adds to the confidence with
which the results from this study can be interpreted.5

Considerable improvements in antimicrobial stewardship were seen when comparing the
group of patients receiving a consult to those that did not. This enhancement in stewardship was
primarily via reduced utilization of antipseudomonal coverage, vancomycin, and ceftriaxone,
which demonstrated the key role that such programs can have on selecting therapy with an
appropriately narrow spectrum. One way by which OPAT can reduce costs and improve patient
outcomes comes via the involvement of infectious disease specialists to improve the selection of
appropriately narrow spectrum antimicrobials. By avoiding the use of overly broad coverage, the
risk of off target eradication of the gut microbiome and subsequent development of a Clostridium
difficile infection can be significantly reduced. Beyond the clinical impact of this variety of
infectious diarrhea, this microbe leads to 4.8 billion dollars in additional costs to hospitals in the
United States annually.6 For example, unnecessary use of ceftriaxone, a cephalosporin utilized
for a variety of infections, has become a potential target for antimicrobial stewardship programs
due to its common use and propensity for causing this type of infection.6,7 It is imperative that
therapies are selected appropriately to only cover the types of microorganisms likely to be
causing the patient’s infection, and narrowed when culture and susceptibility data are available,
which is a major point of impact for pharmacist-led OPAT services.
The difference in readmissions seen for patients without a consult sent to a SAR or ECF
highlights the value of including a dedicated infectious disease clinical pharmacy specialist to
coordinate careful monitoring during the course of OPAT. Especially when utilizing agents
requiring therapeutic drug monitoring, such as vancomycin or aminoglycosides, the potential for
significant adverse effects is considerable, and lack of lab value availability during the course of
OPAT has been noted to be a significant risk factor for readmission, which may partially explain
the difference seen here.8 The potentially increased debility or acuity of patients more likely to
be sent to a SAR or ECF in comparison to a patient able to be sent home could have contributed
to this observation, but such a difference was not seen amongst patients sent to these facilities
after receiving a consult.
The need for appropriate monitoring and communication between healthcare systems
should be given careful consideration prior to the implementation of OPAT. One report noted
that 26% of sites surveyed had a team specifically designated to handle OPAT cases.5 A survey
of practitioners involved in an OPAT service indicated that up to 70% had seen such therapy
implemented without a consult from an ID specialist, and another study showed the addition of a
pharmacist or ID physician or pharmacist to an OPAT team raised adherence to monitoring by
32% and 64%, respectively.9, 10 One study showed that cases reviewed by an ID physician led to
changes in therapy from parenteral to oral agents in 27-40% of cases.9 This shows the value of a
dedicated OPAT team’s ability to improve patient care via appropriate selection of antimicrobial
therapy from a therapeutic perspective, which often reduces costs.
While poor communication can be a barrier to the success of OPAT, adverse effects have
been cited as the primary reason for OPAT discontinuation or therapy modification in 3-5% of
cases.9 A survey of infectious disease physicians conducted in 2012 showed that only 22% of the
OPAT programs in which they worked had a way to track medication errors, “near misses”, or
adverse events.5 Additionally, it is of utmost importance that patients who are to receive OPAT
be carefully selected to ensure that they have to appropriate social and financial support to
receive therapy at home, an infusion center, or another location. The potential ramifications for
patients inappropriately selected for outpatient therapy include both clinical decompensation as
well as the potential for enhanced resistance by the responsible pathogen due to incomplete
eradication.

Several limitations should be considered when interpreting the results of the study. The
small sample size and timing of the study period at the advent of the program could have
impacted the results. Additionally, the significantly lower number of eligible non-consult
patients noted previously was a phenomenon that should also be considered. This trend could
possibly have been due to the novelty of the new program or increased provider confidence in
the utilization of a formalized OPAT program able to more consistently offer improved
monitoring and follow up after discharge. The lack of assessments related to comorbidities,
severity of infection, or causative pathogen limit the generalizability of these findings. Finally,
due to the method by which cost data for the non-consult was requested, namely via use of ICD10 coding, a certain level of uncertainty was introduced. It was hypothesized that this may have
been due to inconsistent coding practices and likely did not skew the results in favor of either
group, but it should be noted nonetheless.
As OPAT services continue to expand in the United States, further investigations
utilizing larger sample sizes and examining shifting trends in patient outcomes should be
conducted in order to further assess the value of the program and monitor for potential quality
improvement opportunities. Furthermore, patient and provider satisfaction data could be included
to better assess the improvements in quality of life and perception of value associated with the
program, respectively. This study serves as a promising indication for the potential patient care
improvements related to antimicrobial stewardship and improved patient outcomes that OPAT
services can offer to their patients.
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